<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="125686">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01466257</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000715520</org_study_id>
    <secondary_id>ECOG-E5397T2</secondary_id>
    <nct_id>NCT01466257</nct_id>
  </id_info>
  <brief_title>Biomarkers in Patients With Head and Neck Cancer</brief_title>
  <official_title>Detection of DNA Mutations in Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will
      respond to treatment.

      PURPOSE: This research study is studying biomarkers in patients with head and neck cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To determine the mutation rates of HRAS and PIK3CA in patients with head and neck
           squamous cell carcinoma (HNSCC) who were treated with cisplatin/placebo and
           cisplatin/cetuximab on protocol ECOG-E5397.

        -  To determine the association between HRAS or PIK3CA mutation status and clinical
           benefits (i.e., response, progression-free survival, and overall survival) in patients
           treated with cisplatin/cetuximab compared with those receiving cisplatin/placebo on
           protocol ECOG-E5397.

      OUTLINE: DNA is isolated from one unstained slide per patient. The mutations in HRAS and
      PIK3CA are determined using BEAMING technology.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Mutation rates of HRAS and PIK3CA</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Treated on protocol ECOG-E5397

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine H. Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center</affiliation>
  </overall_official>
  <verification_date>November 2011</verification_date>
  <lastchanged_date>November 2, 2011</lastchanged_date>
  <firstreceived_date>November 2, 2011</firstreceived_date>
  <responsible_party>
    <name_title>Robert L. Comis</name_title>
    <organization>ECOG Group Chair's Office</organization>
  </responsible_party>
  <keyword>metastatic squamous neck cancer with occult primary squamous cell carcinoma</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IVA squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IVA squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IVA squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IVA squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IVB squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IVB squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IVB squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IVB squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IVC squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IVC squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IVC squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IVC squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>untreated metastatic squamous neck cancer with occult primary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
